Stock LYTIX LYTIX BIOPHARMA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lytix Biopharma

Equities

LYTIX

NO0010405780

Biotechnology & Medical Research

Real-time Oslo Bors
Other stock markets
 08:47:34 2024-05-07 am EDT 		5-day change 1st Jan Change
5.6 NOK +0.36% Intraday chart for Lytix Biopharma 0.00% +15.23%
Apr. 25 Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity CI
Apr. 10 Lytix Biopharma to Raise Up to NOK55 Million via Share Offering MT

Valuation

Fiscal Period: December 2023 2024 2025
Capitalization 1 223.6 223.6 -
Enterprise Value (EV) 1 194.7 161.8 223.6
P/E ratio - - -
Yield - - -
Capitalization / Revenue 48.8 x 35.5 x 17.2 x
EV / Revenue 48.8 x 25.7 x 17.2 x
EV / EBITDA -2.01 x -2.29 x -4.87 x
EV / FCF - - -
FCF Yield - - -
Price to Book - - -
Nbr of stocks (in thousands) 40,068 40,068 -
Reference price 2 5.580 5.580 5.580
Announcement Date 2/29/24 - -
1NOK in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025
Net sales 1 - 3.991 6.3 13
EBITDA 1 - -96.72 -70.7 -45.9
EBIT 1 - -96.78 -70.7 -45.9
Operating Margin - -2,425.08% -1,122.22% -353.08%
Earnings before Tax (EBT) -56.01 -87.94 - -
Net income -56.01 -87.94 - -
Net margin - -2,203.38% - -
EPS - - - -
Free Cash Flow - - - -
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 2/16/23 2/29/24 - -
1NOK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025
Net Debt 1 - - - -
Net Cash position 1 - 49.6 61.8 -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - - - -
ROA (Net income/ Total Assets) - - - -
Assets - - - -
Book Value Per Share - - - -
Cash Flow per Share - - - -
Capex - - - -
Capex / Sales - - - -
Announcement Date 2/16/23 2/29/24 - -
1NOK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LYTIX BIOPHARMA Stock Lytix Biopharma
+14.81% 20.64M
MODERNA, INC. Stock Moderna, Inc.
+22.81% 46.81B
LONZA GROUP AG Stock Lonza Group AG
+46.62% 41.29B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.88% 41.37B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.33% 26.06B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.00% 19.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.43% 11.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.73% 12.39B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.48% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. LYTIX Stock
  4. Financials Lytix Biopharma
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW